IHI iShares U.S. Medical Devices ETF

iShares U.S. Medical Devices ETF (IHI) currently reports 47 stock positions (subject to change), placing it in the balanced in breadth range by holdings breadth. The top line-up is ABT (17.27%), ISRG (15.36%), SYK (10.77%), with ABT as the largest single weight at 17.27%. Together, the top three holdings account for 43.40%, which creates a leadership-driven return profile where the top names carry disproportionate influence over fund outcomes. In aggregate, the construction reflects a balance between directional conviction and the diversification benefits that come from a broader holding set.

On the question of capital productivity, ROIC is 15.34%, WACC is 9.42%, and the economic spread is 5.92%. On balance, returns on capital just exceed funding costs, implying limited but real value creation at the margin. Supporting metrics show ROE at 14.15% and ROA at 7.77%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio that is value-creative but with less room for execution slippage.

On a multiple basis, the portfolio trades at trailing P/E of 32.08, forward P/E of 20.63, PEG of 2.12. The trailing-to-forward compression is notable, pointing to an earnings growth narrative that, if delivered, would make current valuations more defensible. At this PEG level, valuation is defensible given the growth outlook, though there is limited margin of safety against estimate disappointments. The portfolio's holdings carry a current ratio of 2.73, pointing to strong short-term financial health. The valuation setup is broadly consistent with a market that is pricing growth without being reckless about it — a balanced but not cautious stance.

The margin stack reads as follows: gross margin sits at 61.21%, operating margin at 21.18%, and free cash flow margin at 18.41%. Gross margins at this level typically indicate businesses with structural pricing advantages and low direct cost sensitivity. The portfolio's operating margins are solid, pointing to holdings where overhead management is a relative strength. FCF margins are constructive here, reflecting holdings that generate cash reliably after reinvestment requirements. The margin profile across gross, operating, and free cash flow levels is consistently strong — a rare combination that typically indicates durable business quality.

Where growth and expectations intersect, the estimated 12-month price change of 31.79%, where the forward target set implies considerable headroom versus current levels, while TTM revenue growth of 11.52% suggesting the portfolio's holdings are growing revenues at a measured, sustainable pace. The projected 12-month EPS growth rate of 55.5% is a standout component of the forward case — meaningful earnings expansion at this scale typically warrants attention from growth-oriented investors. Both signals are useful lenses, but they tend to diverge most sharply near inflection points in both business fundamentals and market sentiment. The durability of both the operating trend and analyst optimism will determine whether the current setup translates into measurable near-term returns. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Putting all the pieces together, the fundamental picture is one of the more convincing setups in these metrics — strong capital returns, reasonable pricing, and a healthy forward outlook.

The views expressed above are derived from quantitative data only and should not be relied upon as financial advice. Investment decisions should be based on your own research and risk tolerance.